The U.S. FDA has approved a new wearable form of Sanofi’s blood cancer drug, Sarclisa, offering a more convenient alternative for multiple myeloma patients previously reliant on intravenous infusions. This marks the first FDA approval for cancer drug delivery via an on-body injector attached to the skin, aiming to improve patients’ quality of life and treatment adherence. This advancement highlights ongoing progress in medical technology and personalized medicine.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.devdiscourse.com/article/health/3948846-sanofis-revolutionary-blood-cancer-drug-a-breakthrough-in-wearable-injection-technology
